AzTrials
AzTrials

Hip FracturesHIP ATTACK-2NCT04743765

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

A study testing Accelerated medical clearance and surgery in people with Hip Fractures and Myocardial Injury, run by Population Health Research Institute at 77 sites in 20 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. Read more about this study

Who is it for?
Ages 45 years and older
Conditions the study is for
Hip Fractures, Myocardial Injury
What is being tested?
Accelerated medical clearance and surgery
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,100 participants
Where
77 sitesin 20 countries
Study dates
22 Nov 2021to 30 Nov 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • age ≥45 years;
  • diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;
  • troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and
  • informed consent.

Who cannot join

  • taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe;
  • patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);
  • patients with peri-prosthetic fracture, open fracture or bilateral fractures;
  • patients requiring an emergency surgery for another reason (e.g., subdural hematoma);
  • patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock;
  • patients refusing consent; or
  • patients previously enrolled in HIP ATTACK-2.

Trial locations and contacts

77 sites in 20 countries. Contact the study team or a site near you to ask about taking part.

Valerie Harvey contact

905-297-3479 ext. 40793

valerie.harvey@phri.ca

77 sites in 20 countries

United States23 sites

  • University of Michigan

    Ann Arbor, Michigan, 48109

    Active, not recruiting

  • Emory University at Grady Memorial Hospital

    Atlanta, Georgia, 30322

    Active, not recruiting

  • University of Maryland

    Baltimore, Maryland, 20742

    Active, not recruiting

  • Sinai Hospital of Baltimore

    Baltimore, Maryland, 21215

    Active, not recruiting

  • St. Luke's University Health Network

    Bethlehem, Pennsylvania, 18015

    Active, not recruiting

  • Tufts Medical Center

    Boston, Massachusetts, 02111

    Active, not recruiting

  • Lahey Hospital and Medical Center

    Burlington, Massachusetts, 01805

    Active, not recruiting

  • Chandler Regional Medical Center

    Chandler, Arizona, 85224

    Active, not recruiting

  • Cleveland Clinic

    Cleveland, Ohio, 44195

    Active, not recruiting

  • The University of Texas Southwestern Medical Center (UTSW)

    Dallas, Texas, 75390

    Active, not recruiting

  • The Regents of the University of California

    Davis, California, 95618

    Active, not recruiting

  • The University of Texas Health Science Center at Houston

    Houston, Texas, 77030

    Active, not recruiting

  • University of California, Irvine

    Irvine, California, 92697

    Active, not recruiting

  • University Medical Center of Southern Nevada

    Las Vegas, Nevada, 89102

    Active, not recruiting

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire, 03756

    Active, not recruiting

  • Bryan Medical Center

    Lincoln, Nebraska, 68506

    Active, not recruiting

  • University of Wisconsin

    Madison, Wisconsin, 53715

    Active, not recruiting

  • Froedtert Hospital

    Milwaukee, Wisconsin, 53226

    Active, not recruiting

  • Yale New Haven Hospital

    New Haven, Connecticut, 06520

    Active, not recruiting

  • Oregon Health and Science University

    Portland, Oregon, 97239

    Active, not recruiting

  • Mayo Clinic

    Rochester, Minnesota, 55905

    Active, not recruiting

  • University of Utah

    Salt Lake City, Utah, 84112

    Active, not recruiting

  • Montefiore Medical Center

    The Bronx, New York, 10467

    Active, not recruiting

Other trials in United States

Spain11 sites, 9 recruiting

  • Hospital Universitari Sagrat Cor

    Barcelona, Barcelona, 08029

    Maria del Mar Marti Ejarque, 34 + 933 22 11 11, mmmarti@quironsalud.es

    Laura Ruiz-Villa, MD

    Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona, 08035

    Yaiza Garcia, 34 + 934 89 30 00, yaiza.garcia@vhir.org

    Ernesto Guerra-Farfan, MD

    Recruiting

  • Hospital Clinic of Barcelona

    Barcelona, Barcelona, 08036

    Montsant Jornet Gibert, MD, 34 + 932 27 54 00, jornet@clinic.cat

    Marina Renau Cerrillo, MD

    Recruiting

  • Hospital de la Santa Creu I Sant Pau

    Barcelona, Barcelona, 08041

    Active, not recruiting

  • Parc Sanitari Sant Joan de Déu

    Barcelona, 08830

    Judit Lopez Luque, 34 + 936 61 52 08, juid.lopez@sjd.es

    Juan Castellanos, MD

    Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, 28034

    Yolanda Diez Remesal, 34 + 913 36 80 00, yolan10@gmail.com

    Yolanda Diez Remesal, MD

    Recruiting

  • Hospital Costa del Sol

    Marbella, Malaga, 29603

    Alicia Lopez, 34 + 951 97 66 69, alicia.lopez@ibima.eu

    Enrique Guerado, MD

    Recruiting

  • Hospital Universitari Parc Tauli

    Sabadell, Barcelona, 08208

    Active, not recruiting

  • Hospital Sant Camil

    Sant Pere de Ribes, Barcelona, 08810

    Alfred Dealbert, MD, 34 + 938 96 00 25, adealbert@csg.cat

    Alfred Dealbert, MD

    Recruiting

  • Hospital Universitario Mutua de Terrassa

    Terrassa, Barcelona, 08221

    Judit Lopez, 34 + 937 36 50 50, jlopezcatena@mutuaterrassa.cat

    Marti Bernaus, MD

    Recruiting

  • Hospital Clinico Universitario de Vallad

    Valladolid, Valladolid, 47007

    Adela Pereda, 34 + 983 42 00 00, aperedama@gmail.com

    Hector Aguado, MD

    Recruiting

Other trials in Spain

Canada7 sites, 6 recruiting

  • University of Alberta Hospital

    Edmonton, Alberta, T6G 2B7

    Active, not recruiting

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, L8N 4A6

    Krysten Gregus, 905-521-2100, gregus@hhsc.ca

    Flavia Borges, MD

    Recruiting

  • Juravinski Hospital

    Hamilton, Ontario, L8V 1C3

    Krysten Gregus, 905-521-2100, gregus@HHSC.ca

    Ameen Patel, MD

    Recruiting

  • CISSS de Laval

    Laval, Quebec, H7M 3L9

    Zoe Masset, 450-668-1010, zoe.masset.cissslav@ssss.gouv.qc.ca

    Maxime Beaumont-Courteau, MD

    Recruiting

  • Victoria Hospital

    London, Ontario, N6A 5W9

    Fatma Alqahwaji, 519-685-8500, Fatma.alqahwaji@lhsc.on.ca

    Reem Ansari, Reem.Ansari@lhsc.on.ca

    Recruiting

  • Markham Stouffville Hospital

    Markham, Ontario, L3P 7P3

    Michelle Dimas, 905-472-7373, mdimas@oakvalleyhealth.ca

    Steve McMahon, MD

    Recruiting

  • Ottawa General Hospital

    Ottawa, Ontario, K1H 8L6

    Katie Mcliquham, 613-722-7000, kmcilquham@ohri.ca

    Robert Feibel, MD

    Recruiting

Other trials in Canada

Pakistan7 sites, 6 recruiting

  • Maroof International Hospital

    Islamabad, ICT, 44000

    Saboora Waris, MD, 92 + 51-111-644-911, saboora.waris@maroof.com.pk

    Hassan Mumtaz, hassan.mumtaz@maroof.com.pk

    Recruiting

  • Shifa International Hospitals Ltd.

    Islamabad, ICT, 44000

    Tehreem Zahid, MD, 92 + 51-846-4646, dr.tehreemzahid@gmail.com

    Sundus Dadan, MD, dada.sundus01@gmail.com

    Recruiting

  • Aga Khan University

    Karachi, Sindh, 74800

    Nida Zehra, 92 + 21 111 911 911, nida.zehra@aku.edu

    Bisma Zubair, bisma.zubair@aku.edu

    Recruiting

  • Indus Hospital & Health Network

    Karachi, Sindh

    Ayaz Mansoor, MD, 92 + 021 35112709, ayaz.mansoor@tih.org.pk

    Areeba Jabeen, MD, areeba.jabeen@tih.org.pk

    Recruiting

  • Ghurki Trust Teaching Hospital

    Lahore, Punjab Province, 54000

    Active, not recruiting

  • Hayat Abad Medical Complex

    Peshawar, KPK, 25000

    Muhammad Waqar, MD, 92 + 091-9217140-47, wkhan43@gmail.com

    Muhammad Arif, MD

    Recruiting

  • Combined Military Hospital

    Rawalpindi, Punjab Province, 46000

    Ahmed Mushtaq Khan, MD, 92 + 51 9273426, surgeon760@gmail.com

    Muhammad Asif Rasheed, MD, asifmalik256@hotmail.com

    Recruiting

Other trials in Pakistan

India5 sites, 3 recruiting

  • Government TD Medical College

    Alappuzha, Kerala, 688005

    Active, not recruiting

  • Bangalore Baptist Hospital

    Bangalore, Karnataka, 560024

    Praveena Stanislas, 91 + 804-640-4700, praveebio@gmail.com

    Tatarao Rao, tatarao777@gmail.com

    Recruiting

  • All India Institute of Medical Sciences (AIIMS)

    New Delhi, National Capital Territory of Delhi, 110029

    Nasim Mansoori, MD, 91+885-118-7292, nasim.aiims@gmail.com

    Vijay Sharma, MD

    Recruiting

  • JIPMER

    Puducherry, Puducherry, 605006

    Avinash Anantharaj, MD, 91 + 772-805-0413, dravinash@gmail.com

    Ranjith Kumar Mekala, MD

    Recruiting

  • Government Medical College

    Trivandrum, Kerala, 695011

    Active, not recruiting

Other trials in India

Italy4 sites, 4 recruiting

  • Galliera Hospital

    Genova, 16128

    Claudia Brusasco, MD, 39 + 010-56321, claudia.brusasco@galliera.it

    Maria Laura Raimondo, MD

    Recruiting

  • Ospedale San Raffaele S.r.l.

    Milan, 20132

    Giacomo Placella, MD, 39 + 02-26431, placella.giacomo@hsr.it

    Vincenzo Salini, MD

    Recruiting

  • Ospedale Galeazzi SpA

    Milan, 20157

    Dario Pellegrino, 39 + 02-8350-0010, dar.pellegrini@gmail.com

    Serena Favoro, 39 + 02-8350-0010, Serena.Favaro@grupposandonato.it

    Recruiting

  • Hospital of Perugia

    Perugia, Umbria, 06129

    Marta Baroni, MD, 39 + 075-5781, marta.baroni@ospedale.perugia.it

    Carmelinda Ruggiero, MD

    Recruiting

Other trials in Italy

Chile2 sites, 2 recruiting

  • Pontifica Universidad Catolica de Chile

    Santiago, RM, 83300024

    Karen Azagra, 56 + 2-2633-2051, karen.azagra@uc.cl

    Fernando Altermatt, MD

    Recruiting

  • Clinica Santa Maria

    Santiago, 7520378

    Javiera Vasquez, MD, 56 + 2-2913-0000, javiera.vasquezm@gmail.com

    David Torres, MD

    Recruiting

Other trials in Chile

Finland2 sites, 1 recruiting

  • South Karelia Central Hospital

    Lappeenranta, 53130

    Active, not recruiting

  • Tampere University Hospital

    Tampere, 33521

    Aleksi Reito, MD, 358 + 3-311611, Aleksi.reito@pshp.fi

    Aleksi Reito, MD

    Recruiting

Other trials in Finland

Mexico2 sites

  • Christus Muguerza del Parque

    Chihuahua City, Chihuahua, 31000

    Active, not recruiting

  • Cruz Verde Guadalajara

    Guadalajara, Jalisco, 44410

    Active, not recruiting

Other trials in Mexico

Netherlands2 sites, 2 recruiting

  • Stichting OLVG

    Amsterdam, 1091

    Esther Scheibeler, 31 + 20-599-9111, E.Scheijbeler@olvg.nl

    Okke Hoonhout, MD, O.hoonhout@olvg.nl

    Recruiting

  • Deventer Hospital

    Deventer, Overijssel, 7416 SE

    Ellie Landman, 31 + 570-535-353, e.b.m.landman@dz.nl

    Ydo Kleinlugtenbelt, MD

    Recruiting

Other trials in Netherlands

South Africa2 sites, 1 recruiting

  • Stellenbosch University - Tygerberg Hospital

    Cape Town, Western Cape, 7505

    Active, not recruiting

  • Groote Schuur Hospital

    Cape Town, Western Cape, 7925

    Simphiwe Gumede, 27 + 21 404 9111, simphiwe.gumede@uct.ac.za

    Sithombo Maqungo, MD

    Recruiting

Other trials in South Africa

United Kingdom2 sites, 2 recruiting

  • Chelsea and Westminster Hospital

    London, SW10 9NH

    Julie Logan, 44 + 20-3315-8000, julie.logan11@nhs.net

    Laura Martins, 44 + 20-3315-8000, l.martins2@nhs.net

    Recruiting

  • West Middlesex University Hospital

    Middlesex, TW7 6AF

    Amrinder Sayan, 44+ 208-321-5181, amrinder.sayan@nhs.net

    Jamie Gonzales, 44 + 208-321-5181, jamie.gonzales@nhs.net

    Recruiting

Other trials in United Kingdom

Australia1 site, 1 recruiting

  • The John Hunter Hospital

    New Lambton Heights, New South Wales, 2305

    Debra McDougall, 61 + 2-4921-3000, Debra.McDougall@health.nsw.gov.au

    Zsolt Balogh, MD

    Recruiting

Other trials in Australia

Belgium1 site

  • Cliniques Universitaires Saint Luc - University Catholic of Louvain

    Woluwe-Saint-Lambert, Brussels Capital, 1200

    Active, not recruiting

Other trials in Belgium

Brazil1 site, 1 recruiting

  • University of São Paulo

    São Paulo, São Paulo, 05403010

    Maria (Adelaide) Gongalves, MD, 55 + 11-3091-3116, Adelaidemiranda99@gmail.com

    Kodi Kojima, MD

    Recruiting

Other trials in Brazil

Hong Kong1 site, 1 recruiting

  • Queen Mary Hospital

    Hong Kong

    Grace Ho, 852 + 2255-3838, gracehpy@hku.hk

    Christian Fang, MD

    Recruiting

Other trials in Hong Kong

Malaysia1 site, 1 recruiting

  • University of Malaya Medical Centre

    Kuala Lumpur, 59100

    Shwen Nee Chong, MD, 60 + 3-7949-4422, swhennee@gmail.com

    Chew Yin Wang, MD

    Recruiting

Other trials in Malaysia

Nepal1 site, 1 recruiting

  • B and B Hospital

    Lalitpur, Bagmati, 44700

    Satish Prasad Barnawal, MD, 977 + 1-5970999, satishprasadbarnawal@gmail.com

    Bibek Banskota, MD

    Recruiting

Other trials in Nepal

Poland1 site, 1 recruiting

  • SPZOZ Myslenice

    Myślenice, Malopolska, 32-400

    Ilona Nowak-Kózka, 48 + 12-273-03-55, ilonnowak@gmail.com

    Mateusz Sitkowski, mateusz.sitkowski@yahoo.com

    Recruiting

Other trials in Poland

Saudi Arabia1 site, 1 recruiting

  • King Faisal Specialist Hospital

    Riyadh, Riyadh Region, 11211

    Fahad Alotaibi, 966 + 11 464 7272, falotaibi7@kfshrc.edu.sa

    Husam Alrumaih, MD

    Recruiting

Other trials in Saudi Arabia

About this study

Official title: HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 (HIP ATTACK-2) Trial

The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.

Being tested
Accelerated medical clearance and surgery
Medical subject headings
Hip Fractures

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Accelerated medical clearance and surgeryOther

    Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.

Study groups in NCT04743765
Study groupRoleWhat they receive
Accelerated medical clearance and surgeryExperimentalAccelerated medical clearance and targeted arrival to the operating room within 6 hours of eligibility criteria met.
Receives: Other: Accelerated medical clearance and surgery
Standard surgical careNo interventionHip fracture repair and surgical care according to treating institution guidelines.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. All cause mortality

    Death due to all causes

    Measured: Within 90 days post randomization

Secondary outcomes (10)

  1. Ability to independently walk 3 meters

    Ability to independently walk 3 meters (10 feet) or across a room without human assistance. Patients who require a cane or walker, but not human assistance, will be classified as able to walk independently. Patients who require assistance to get out of a chair, but can walk independently once they get up, will be classified as able to walk independently.

    Measured: Within 90 days post randomization

  2. Composite of major complications

    Composite includes vascular and nonvascular mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke.

    Measured: Within 90 days post randomization

  3. Vascular mortality

    Any death with a vascular cause and includes those deaths following a myocardial infarction, sudden cardiac arrest, stroke, cardiac revascularization procedure (i.e., percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery), heart failure, pulmonary embolus, cardiovascular hemorrhage, or deaths due to an unknown cause

    Measured: Within 90 days post randomization

  4. Nonvascular mortality

    Any death due to a clearly documented non-vascular cause.

    Measured: Within 90 days post randomization

  5. Myocardial Infarction

    Diagnosis of MI according to 4th universal definition of myocardial infarction

    Measured: Within 90 days post randomization

  6. Acute Congestive Heart Failure

    at least one clinical sign(s) or symptom(s) (e.g elevated jugular venous pressure, respiratory rales/crackles, crepitations, hypoxia, tachypnea or presence of S3) with at least one of the following:

    1. radiographic findings (i.e., vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary edema) or point of care ultrasound findings (i.e., bilateral B-lines, bilateral pleural effusion, elevated jugular venous pressure, dilated inferior vena cava with respiratory variation less than 50%) OR
    2. heart failure treatment implemented with diuretics with documented clinical improvement.

    Measured: Within 90 days post randomization

  7. Stroke

    Either - 1. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting more than 24 hours or leading to death; or 2. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting less 24 hours with a positive neuroimaging consistent with a stroke

    Measured: Within 90 days post randomization

  8. Time from randomization to hospital discharge

    Length of hospital stay from randomization to hospital discharge

    Measured: Within 90 days post randomization

  9. Delirium

    1. Patient meets the criteria for delirium on any in-person 3D-CAM or CAM administered; OR
    2. Positive history of delirium in the 7 days after randomization based on the review of hospital health records.

    Measured: Within 7 days and 90 days post randomization

  10. Moderate to severe pain

    Moderate to severe pain is defined as any pain score ≥3 on 10 points scale.

    Measured: Within 7 days and 90 days post randomization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Feb 2021
  2. Study start22 Nov 2021
  3. Primary completion31 Aug 2027 (estimated)
  4. Study completion30 Nov 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
1,100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04743765
Sponsor's protocol ID
v2.0_20230608
Acronym
HIP ATTACK-2
Status last verified
Sep 2025
First submitted
3 Feb 2021
Last updated
26 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The Population Health Research Institute (PHRI) is the sponsor of this trial. The PHRI believes the dissemination of clinical research results is vital and sharing of data is important. PHRI prioritizes access to data analyses to researchers who have worked on the trial for a significant duration, have played substantial roles, and have participated in raising the funds to conduct the trial. PHRI balances the length of the research study, and the intellectual and financial investments that made it possible with the need to allow wider access to the data collected. Data will be disclosed only upon request and approval of the proposed use of the data by a Review Committee.

Questions about this trial

What is this clinical trial studying?

A study testing Accelerated medical clearance and surgery in people with Hip Fractures and Myocardial Injury, run by Population Health Research Institute at 77 sites in 20 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 77 sites in United States, Spain, Canada, Pakistan, India and 15 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Valerie Harvey (905-297-3479 ext. 40793, valerie.harvey@phri.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

All cause mortality (time frame: Within 90 days post randomization). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04743765.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in